BC Week In Review | May 2, 2016
Company News

Aviragen, HealthCare Royalty Partners deal

Aviragen sold an undisclosed portion of its Inavir laninamivir octanoate royalty rights to HealthCare Royalty Partners for $20 million. Aviragen said it receives about $4.5 million annually from Inavir royalties. Daiichi Sankyo Co. Ltd. (Tokyo:4568,...
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
BC Week In Review | Aug 4, 2014
Clinical News

Inavir laninamivir octanoate: Phase II data

Top-line data from 248 patients with PCR-confirmed influenza A or B infection in the intent-to-treat (ITT) population of the double-blind, international Phase II IGLOO trial showed that 40 and 80 mg laninamivir octanoate delivered via...
BioCentury | Aug 4, 2014
Finance

Highlights of weekly biotech stock moves

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) fell $4.44 (41%) to $6.39 on Monday after receiving a complete response letter from FDA for an NDA for Zalviso sufentanil sublingual tablet system to treat moderate-to-severe acute pain. AcelRx said...
BC Extra | Aug 2, 2014
Clinical News

Biota's laninamivir octanoate misses in Phase II influenza

Biota Pharmaceuticals Inc. (NASDAQ:BOTA) said laninamivir octanoate delivered via TwinCaps dry-powder inhaler missed the primary endpoint of improving median time to alleviation of influenza symptoms vs. placebo in the intent-to-treat (ITT) population of the Phase...
BioCentury | Jul 14, 2014
Finance

2Q Stock Wrap-Up: Large and in charge

In contrast to the first quarter in which all market cap segments gained ground, only the large caps finished 2Q14 in the black. Gainers outnumbered decliners 20-12 in the over $5 billion segment, which was...
BC Week In Review | Jun 23, 2014
Company News

Biota Pharmaceuticals Inc, U.S. Department of Health and Human Services infectious news

Biota will reduce headcount by 50 (67%) to 25 and close its Melbourne facility by June 30, 2015. All of the cuts will come from Australia and the remaining 10 Australian employees will move to...
BC Week In Review | May 12, 2014
Company News

Biota Pharmaceuticals, U.S. Department of Health and Human Services infectious news

Biota said HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA) terminated a 2011 contract worth up to $231 million to develop the company's laninamivir...
BioCentury | May 12, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) slipped $2.25 to $152.87 last week after FDA granted full approval to Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS). The agency granted accelerated approval for Soliris for...
BC Extra | May 9, 2014
Company News

BARDA terminates Biota's laninamivir octanoate contract

Biota Pharmaceuticals Inc. (NASDAQ:BOTA) said HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA) terminated a 2011 contract worth up to $231 million to develop...
Items per page:
1 - 10 of 72